JP Morgan's Take on Dr Reddy’s Laboratories

JP Morgan has an underweight rating on Dr Reddy’s Laboratories with a target price of Rs 1,060. Analysts highlight concerns over weak core EBITDA margins and lackluster growth in India, alongside uncertainties regarding niche launches in the US.

Citigroup's Buy Rating on Biocon

Citigroup recommends a buy on Biocon, setting a target price at Rs 430. Despite a decline in ex-gRevlimid EBITDA margin, the firm notes a 4% annual growth in biosimilars, pointing to a competitive pricing environment.

Nomura's Optimistic Outlook on Zydus Life

Nomura has issued a 'buy' rating for Zydus Life, with a target price of Rs 1,140. The approval for gCopaxone, estimated at a $600 million market size, is a key factor, though future competition from Biocon and Dr Reddy’s is anticipated.

Macquarie's Caution on Swiggy

Macquarie maintains an underperform rating on Swiggy, with a target price of Rs 260. The platform's challenges are underscored by delayed margin break-even expectations and narrowing gaps with competitors.

Goldman Sachs' Confidence in Pidilite

Goldman Sachs affirms a buy rating on Pidilite, targeting Rs 3,475. Strong volume growth and optimism for FY26, driven by an improving consumption environment, are cited as positive indicators.

Disclaimer: The opinions and recommendations are those of the analysts and do not reflect the views of The Times of India. Consult a financial advisor before making investment decisions.